Skip to main content

Table 2 Multivariate analysis of overall survival for patients undergoing NACT

From: Neoadjuvant chemotherapy for patients with international federation of gynecology and obstetrics stages IB3 and IIA2 cervical cancer: a multicenter prospective trial

 

CR/PR (n = 227)

SD/PD (n = 91)

NACT (n = 318)

 

Adjust p-Value

Adjust OR (95%CI)

Adjust p-Value

Adjust OR (95%CI)

Adjust p-Value

Adjust OR (95%CI)

Age

\

\

0.108

0.925 (0.841, 1.017)

\

\

Hb

0.093

0.978 (0.953, 1.004)

\

\

0.300

0.989 (0.968, 1.010)

Tumor size

before NACT

0.760

0.926 (0.563, 1.522)

0.945

1.029 (0.457, 2.319)

0.650

1.082 (0.771, 1.518)

after NACT

0.055

1.928 (0.987, 3.769)

0.463

1.306 (0.641, 2.660)

0.096

1.246 (0.962, 1.614)

Approach of surgery

\

\

\

\

0.085

0.305 (0.079, 1.176)

FIGO

0.272

1.920 (0.599, 6.152)

\

\

\

\

> 1/2 depth of cervical invasion

0.154

2.243 (0.739, 6.806)

0.325

2.357 (0.428, 12.97)

0.046

2.608 (1.017, 6.691)

LVSI

\

\

\

\

0.242

1.901 (0.648, 5.577)

Vagina involvement

0.523

0.427 (0.031, 5.831)

0.165

6.154 (0.472, 80.171)

0.676

1.476 (0.238, 9.157)

Uterus involvement

\

\

\

\

0.927

1.076 (0.227, 5.109)

Lymph node metastasis

0.464

1.591 (0.46, 5.507)

\

\

0.938

1.042 (0.368, 2.946)

  1. Candidate variables with a p-value of < 0.2 in univariate analysis of Cox proportional hazards regression were included in the multivariable model and “\” meant the corresponding factor was not included
  2. Abbreviations: OR Odds ratio, Hb Hemoglobin concentration, Plt Platelet concentration, BMI Body mass index, SCCA Squamous Cell Carcinoma Antigen, NACT Neoadjuvant chemotherapy, LVSI Lymphovascular space invasion